Novo Nordisk Files Patent Lawsuits to Block Mylan’s Generic Ozempic

Novo Nordisk has initiated two patent infringement lawsuits aimed at preventing Mylan from producing a generic version of Ozempic. Represented by Fenwick & West, Novo Nordisk filed one complaint in the District of Delaware and followed it up with a nearly identical lawsuit in the Northern District of West Virginia. The legal maneuvers highlight the company’s efforts to maintain its market position for the diabetes medication. For further details, you can read the original article here.